These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 16689373)

  • 1. [Use of angiotensin type II receptor blockers as a potential strategy for chronic heart failure].
    Nakano A; Kitakaze M
    Nihon Rinsho; 2006 May; 64(5):910-6. PubMed ID: 16689373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure: is there a role for angiotensin II receptor blockers?
    Boucher M; Ma J
    Issues Emerg Health Technol; 2002 Sep; (38):1-4. PubMed ID: 12243202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
    Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP
    Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?
    Pourdjabbar A; Lapointe N; Rouleau JL
    Can J Cardiol; 2002 May; 18 Suppl A():7A-14A. PubMed ID: 12045788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR; Krum H
    Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    Levy PD; Nandyal D; Welch RD; Sun JL; Pieper K; Ghali JK; Fonarow GC; Gheorghiade M; O'Connor CM
    Am Heart J; 2010 Feb; 159(2):222-230.e2. PubMed ID: 20152220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
    Cohn JN
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S38-40. PubMed ID: 17199220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Singh RK; Barker S
    Curr Opin Investig Drugs; 2005 Mar; 6(3):269-74. PubMed ID: 15816503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S; Kitakaze M
    Nihon Rinsho; 2003 May; 61(5):821-6. PubMed ID: 12755009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A hard look at angiotensin receptor blockers in heart failure.
    Gring CN; Francis GS
    J Am Coll Cardiol; 2004 Nov; 44(9):1841-6. PubMed ID: 15519017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.